Paxista Nirmatrelvir 150mg Tablets Description :
Nirmatrelvir is an oral protease inhibitor that is dynamic against MPRO, a viral protease that assumes a fundamental part in viral replication by cutting the 2 viral polyproteins.1 It has exhibited antiviral movement against all Covids that are known to taint humans.2 Nirmatrelvir is bundled with ritonavir (as Paxlovid), a solid cytochrome P450 (CYP) 3A4 inhibitor and pharmacokinetic helping specialist that has been utilized to support HIV protease inhibitors. Coadministration of ritonavir is expected to increment nirmatrelvir focuses to the objective remedial reach. The Food and Medication Organization (FDA) gave a Crisis Use Approval (EUA) for ritonavir-supported nirmatrelvir on December 22, 2021, for the treatment of Coronavirus.
Brand Name:
Paxista, a branded drug Nirmatrelvir 150 mg and Ritonavir 100 mg are the ingredients. Azista Healthcare Pvt Ltd. manufactured Shape: tablet Packing: 30 Tablets per Pack Product description Nirmatrelvir is an oral active 3C-like protease inhibitor and an antiviral drug created by Pfizer. It is marketed as Paxlovid and is a component of the nirmatrelvir/ritonavir combination therapy for COVID-19.
Paxista, a branded drug Nirmatrelvir 150 mg and Ritonavir 100 mg are the ingredients. Astrica Healthcare Pvt Ltd. manufactured Shape: tablet Packing: 30 Tablets per Pack
Product Specification
| Packaging Size | Combipack |
| Composition | Nirmatrelvir ritonavir |
| Treatment | Covid |
| Prescription/Non prescription | Prescription |
| Form | Tablet |
| Shelf life | Year |
| Drug Name | Paxista |
| Pack Type | 3×10 |
| Packing Type | 3×10 |
| No | N |
